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Background: The utility of cardiac device-based intrathoracic monitoring (OptiVol, Medtronic Inc.,
Minneapolis, MN,USA) for congestive heart failure (CHF) exacerbation has not been evaluated in pediatric
or congenital heart disease patients.
Methods: This was a retrospective study of all patients at a single center with an endocardial OptiVol
capable device. OptiVol index values were collected in 2-week bins from January 2007 to December 2010.
The clinical outcomes were CHF exacerbation defined as hospitalization or medication change for CHF
and device-treated ventricular arrhythmia based on remote or in-office device interrogation. Clinical and
OptiVol data were collected by separate investigators blinded to the other parameter. OptiVol data were
correlated to the clinical outcomes to determine sensitivity and predictability for multiple threshold values
in the entire cohort and pediatric and congenital subgroups.
Results: Forty-seven patients were included. A total of 1,106 months of OptiVol data were collected.
Median age of the cohort was 18 years (range 6–58 years). There were 23 pediatric, median age
13 years (range 6–16), at device implant, and 18 patients, median age 31 years (range 13–58), considered
at risk for heart failure at implant. There were three heart failure exacerbations and 17 treated ventricular
arrhythmias. The study population-specific positive predictive value (PPV) of OptiVol was low (sensitivity
33% and PPV ≤4.4%) for both CHF exacerbation and arrhythmias in all analyzed groups.
Conclusions: The sensitivity and positive predictive value of intrathoracic impedance monitoring was
low in this population of adult congenital and pediatric patients. Recent improvements to the OptiVol
algorithm may decrease these deficiencies. (PACE 2013; 36:994–999)
congestive heart failure, electrophysiology – clinical, defibrillation – ICD
Intrathoracic impedance (ITI) monitoring has
recently been developed as a means to detect
transpulmonary fluid accumulation in patients at
risk for heart failure exacerbation.1 The goal of
transthoracic impedance monitoring is to detect
these physiologic changes before the patient
develops clinical symptoms requiring acute man-
agement or hospitalization. An ITI monitoring
program, OptiVol (Medtronic Inc., Minneapo-
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lis, MN, USA), has been incorporated into
Medtronic implantable cardioverter-defibrillators
(ICDs) since 2007. OptiVol makes daily ITI
measurements, compares them to the individual
patient’s baseline impedance, and computes a
continuous dynamic OptiVol fluid index value
proposed to track changes in fluid content in lung
and other thoracic tissues.2,3 Significant decreases
in ITI values may indicate fluid accumulation and
pending heart failure exacerbation. The trends of
impedance measurements are available upon in-
office or remote device interrogation, allowing the
care team to intervene before symptom onset.
ITI monitoring has been the subject of
multiple trials of adult heart failure patients4–10
and additional publications in the past several
years.11,12 These studies have generally shown
fair sensitivity and fair to poor positive predictive
values ranging from 5% to 60% and suggested a
lower risk of heart failure hospitalization when
using ITI monitoring in these early studies. Van
Veldhuisen, however, showed a higher risk of
hospitalization when utilizing ITI monitoring.13
Two additional studies suggested a possible
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association between ITI measurements and
episodes of ventricular arrhythmia.14,15
This study examines the utility of ITI
monitoring in a population of pediatric and
congenital heart disease (CHD) patients. The
primary goals of the analysis were to identify the
sensitivity and predictive value of ITI monitoring
in this unique population and to determine the
association of ITI changes with arrhythmia in
patients at significant risk for arrhythmia from
cardiomyopathy or channelopathy.
Methods
A retrospective data analysis was performed
on all patients with an OptiVol-capable im-
plantable device. Entry into the study was the
time of implant or establishment of care with the
University of Michigan Congenital Heart Center.
The endpointwas the latter of device explantation,
exit from the University of Michigan Health
system, or December 2010. Patients were excluded
if they had an epicardial device or follow-up less
frequently than once annually. OptiVol data from
time of device implantation to December 31, 2010
were collected from CareLink (Medtronic Inc.)
remote monitoring reports and in-office device
interrogation. The OptiVol data were collected
from the OptiVol Index report.
The OptiVol index (Fig. 1) is an easy to
interpret continuous comparison of the daily ITI
Figure 1. Diagram of impedance measures (top panel)
and OptiVol index report (bottom panel) as provided
in the device interrogation report. Daily impedance
measures are compared to the reference impedance.
Consecutive daily impedance values below the reference
impedance will cause the fluid index to increase. The
physician programmable threshold level is shown at
the nominal 60 Ohm-days. OptiVol fluid index values
crossing the threshold were considered positive for
purposes of the study. Image used with permission from
Medtronic Inc.
measurement to the individual patient’s dynamic
baseline impedance. If the daily impedance is
lower than the reference impedance, the OptiVol
index value goes up. Continued increases in the
OptiVol index value indicate continued decrease
in the daily impedance measurement. Once the
daily measure rises above the baseline, the index
value returns to baseline. The OptiVol threshold,
nominally set at 60 Ohm-days, is a physician-
adjustable threshold value for the OptiVol Index
indicating a possibly significant change in ITI. For
each patient, a peak OptiVol index measurement
(Ohm-days) was recorded for each half-month
period of data and became a binned OptiVol data
point. This peak measurement was recorded in
increments of 20, with a range of 0–200. The
reasons for collecting OptiVol data in this way
were threefold: (1) the OptiVol index report is
easily accessible; (2) the OptiVol index report
increments time into 1-month bins; these bins are
easily divided in half for more frequent peak mea-
surement recording; and (3) the OptiVol threshold
is adjustable in increments of 20. All OptiVol
measurement data were collected by a single
individual blinded to other clinical data (Fig. 1).
Clinical data were collected from existing
medical records and included basic demograph-
ics, cardiac diagnosis, indication for device
implantation, New York Heart Association func-
tional class, use of heart failure medications, and
perceived baseline risk of heart failure based on
structural anatomy. The primary indication for
device implantation was considered to be arrhyth-
mia in all patients with hypertrophic cardiomyoa-
pathy, a genetic channelopathy, or documented
ventricular arrhythmias before implant. For the
purposes of the study, pediatric patients were
defined as those patients entering the study at
≤16 years of age. Patients were considered at risk
for heart failure if they had documented chronic
ventricular dysfunction by echocardiogram or
a systemic right ventricle. The specific clinical
outcome data collected were: occurrence of
documented ventricular arrhythmias, delivered
device therapies, and heart failure exacerbations
which were qualified as documented change in
medication or hospitalization for management of
heart failure symptoms. All clinical data were
collected by a separate individual blinded to the
OptiVol data at the time of collection.
Binned OptiVol data points were associated
with clinical events occurring (1) during the same
or subsequent half-month bin and (2) during the
two consecutive subsequent half-month bins. The
rationale for this approach was to examine the va-
lidity of OptiVol changes to predict clinical events
on a half-month or 1-month timeframe. Specificity
and sensitivity of OptiVol were determined for
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both ventricular arrhythmia and heart failure
exacerbation. Calculations for OptiVol to predict
clinical outcome in the concurrent 1-month period
or subsequent 1-month period were made based
on the prevalence of the outcome in the study
population. Separate analyses were performed
to determine specificity, sensitivity, and positive
predictive value in (1) the entire study cohort,
(2) the subcohort of pediatric patients, and (3)
the subcohort of patients at risk for heart failure.
Separate analyses for sensitivity and population-
specific positive predictive values were calculated
at incremental OptiVol threshold levels between
20 and 200 Ohm-days.
Statistical analysis included calculation of
central tendency for continuous variables and
proportions for categorical variables. Sensitivity,
specificity, and positive predictive value were
calculated using basic 2 × 2 tables of the study
cohort. The Student’s t-test was used to compare
OptiVol Index measurements in patients with
arrhythmia versus patients without arrhythmia.
SAS 9.3 (Cary, NC, USA) was used for t-test
calculations.
Results
Sixty-four OptiVol capable devices were
implanted in 62 patients between January 2007
and September 2010. Seventeen devices were
excluded from the analysis: four were epicardial
implants and the remaining were not followed
at the institution and had insufficient clinical
follow-up records available for analysis. There
were 47 patients (47 devices) included in the
analysis: 18 in the CHF-risk subcohort and 23
in the pediatric subcohort. All included devices
contained the original OptiVol program (not
OptiVol 2.0 included in the Protecta XT device,
Medtronic Inc.). Continuous OptiVol data from
implant to study endpoint were available for 45
of 47 patients (96%). Two patients had missing
data points comprising 2% and 50% of their
total binned data, respectively. Overall, there
were 2,213 total binned OptiVol data points
equivalent to 1,106 months of follow-up data;
median follow-up timewas 24months per patient.
The demographics and clinical characteristics of
the total cohort and the subcohorts are shown
in Table I. Overall 98% of patients had the
device implanted primarily for arrhythmia. The
pediatric subcohort included only one patient
with a perceived risk of heart failure exacerbation.
The prevalence of New York Heart Association
class II heart failure or worse was only 17%
in the total cohort and 39% in the CHF-risk
subcohort. There were only two documented heart
failure exacerbations during the study period, both
occurring in patients in the CHF-risk group. There
were three patients with documented arrhythmias
in the CHF-risk subcohort and five in the pediatric
subcohort.
Table I.
Demographic and Clinical Characteristics in Patients
All CHF-Risk Subcohort Pediatric Subcohort
Variable (n = 47) (n = 18) (n = 23)
Total OptiVol data: (months) 1,106 445 526
Age (years) at implant: mean (range) 22 (6–58) 31 (13–58) 13 (6–16)
Diagnosis: n (%)
TOF 7 (15) 7 (39) 0
TGA 7 (15) 7 (39) 0
Other CHD 3 (6) 3 (17) 0
LQTS 10 (21) 0 5 (22)
HCM 7 (15) 0 7 (30)
CPVT 5 (11) 0 5 (17)
DCM 1 (2) 1 (5) 1 (5)
Arrhythmia indication for implant: n (%) 46 (98) 17 (94) 23 (100)
NYHA HF class ≥ 2: n (%) 8 (17) 7 (39) 1 (5)
# on heart failure medications: n (%) 14 (30) 14 (78) 1 (5)
# with heart failure exacerbation: n (%) 1 (2) 1 (6) 0 (0)
# with arrhythmia events: n (%) 9 (19) 3 (17) 5 (22)
CHD = congenital heart disease; CPVT = catecholaminergic polymorphic ventricular tachycardia; DCM = dilated cardiomyopathy; HCM =
hypertrophic cardiomyopathy; LQTS = Long QT syndrome; NYHA = New York Heart Association heart failure class; TGA = transposition
of the great arteries; TOF = tetralolgy of Fallot.
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Table II.
OptiVol Predictability for Heart Failure Exacerbation
Threshold No. of Threshold Sensitivity % Positive Predictive
No. of Events Level Crossings (95% CI) Value % (95% CI)
Total cohort (A)* 2 140 62 33 (6–76) 3.3 (0.6–12)
Total cohort (B)* 2 80 131 33 (6–76) 1.5 (0.3–6)
CHF-risk subcohort (A)* 2 80 93 33 (6–76) 2.2 (0.4–8)
(A)* = OptiVol measurement correlated to event during concurrent and subsequent half-month period; (B)* = OptiVol measurement
correlated to event during consecutive half periods after OptiVol data point. The pediatric subcohort had no events. CHF = congestive
heart failure; CI = confidence interval.
Table III.
OptiVol Predictability for Ventricular Arrhythmia
Threshold No. of Threshold Sensitivity % Positive Predictive
No. of Events Level Crossings (95% CI) Value % (95% CI)
Total cohort (A)* 17 20 784 31 (17–48) 1.4 (0.7–2.5)
Total cohort (B)* 17 20 784 29 (15–47) 1.3 (0.6–2.4)
CHF-risk subcohort (A)* 9 20 370 30 (14–53) 1.9 (0.8–4)
Pediatric subcohort (A)* 7 20 290 29 (1–58) 1.4 (0.4–4)
(A)* = OptiVol measurement correlated to event during concurrent and subsequent half-month period; (B)* = OptiVol measurement
correlated to event during consecutive half. CHF = congestive heart failure; CI = confidence interval.
The sensitivities and population-specific pos-
itive predictive values were calculated at serial
OptiVol thresholds (20, 40, 60, . . . , 200). Because
70 different analyses were performed, only the
OptiVol thresholds that produced the highest
positive predictive value for each subcohort
analysis are reported in Tables II and III. Also
included in Tables II and III are the total
number of threshold crossings for each analysis.
OptiVol was poorly predictive of both heart failure
exacerbations and arrhythmias in this population
of patients; this was largely a consequence of the
low incidence of the clinical outcome.
Discussion
This study revealed several important find-
ings regarding the utility of ITI monitoring. First,
the positive predictive value in patients consid-
ered to be at risk for heart failure exacerbation was
quite low. Second, the incidence of heart failure
exacerbations in this population of all patients
with an OptiVol-capable ICD from a single center
was also low. Finally, no relationship could be
found between ITI monitoring and arrhythmia
occurrence.
The positive predictive value of a test is in part
a function of the prevalence of disease. Consider-
ing the population as a whole, the incidence of
pediatric heart failure as indicated by a diagnosis
of dilated cardiomyopathy (0.34 per 100,000) is a
tiny fraction of the incidence of congestive heart
failure in the adult population between ages 60
and 80 years (7,200 per 100,000).16 In addition,
the majority of the adult population with ICDs
has them implanted for congestive heart failure.17
The pediatric and CHD population, on the other
hand, more commonly have ICDs implanted for
genetic channelopathies, hypertrophic cardiomy-
opathy, and ventricular arrhythmias subsequent
to repaired CHD.18–20 There are no specific
recommendations or conclusive evidence that
ICDs should be implanted for primary prevention
in pediatric congestive heart failure.
Aside from these factors, the incidence of
heart failure exacerbation in pediatric patients
overall should be considered when determining
the true utility of an ITI monitoring device.
Webster et al.21 performed a national database
study that accounted for 50% of the pediatric
hospitalizations in the United States in 1997. Of
these, 5,600 patients had a diagnosis of heart
failure suggesting a possibility of 11,000 children
hospitalized for heart failure each year. However,
56% of these patients were infants, and heart
failure was only the primary diagnosis in 25%
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of the patients. This indicates that the more
realistic number of potentially preventable heart
failure hospitalizations is only 1,200 per year if
all patients had an ITI monitoring-capable device
with 100% sensitivity to predetect heart failure
exacerbation.
CHD patients specifically have anatomical
constraints to ITI monitoring reliability as the
system is designed to measure thoracic fluid
accumulation occurring with systemic ventricular
failure. Patients with a Fontan circulation will
almost always have an epicardial device. The
utility of impedance monitoring between an
epicardial coil and an abdominal can is not
known. Patients with repaired tetralogy of Fallot
aremore subject to right heart failure exacerbation,
and transpulmonary impedance may not change
appreciably. The primary adult CHD patient may
benefit from ITI monitoring in the patient with
a systemic right ventricle after atrial switch
operation for transposition of the great arteries,
as heart failure in these patients is an almost
expected course. The number of patients with this
specific diagnosis was small, however, and larger
studies may show improved value.
Prior studies have suggested a possible
association between ITI and occurrence of
arrhythmia.14,15 This study did not find such
an association, though the precision with which
changes in Ohm-day values were determined
was much lower than in these prior studies.
Moore et al.14 showed that 64% of ventricular
tachycardia/ventricular fibrillation episodes were
preceded by a mean impedance decrease of
4 Ohms. This study would not have detected these
effects because changes in ITI were determined
from the indexed data and not from the exact
impedance measures. The precision specificity of
such small changes would also be expected to
compromise their predictive value.
Prior adult studies have shown a significant
risk of false positive events. Medtronic literature
on OptiVol3 and a prior publication11 have
provided much information on possible causes of
false positive events. Despite these, the majority
of false positive events have been of unknown
etiology—potentially subclinical episodes of heart
failure exacerbation that resolve spontaneously
or normal physiologic variation. This study
population provides a unique opportunity to see
the risk of false positive events in a population
of patients with no risk for CHF exacerbation.
For example, in the pediatric group, a nominal
OptiVol threshold level of 60 resulted in 205
(10%) of the 2,213 total binned OptiVol index
values being above the threshold and therefore a
false positive event.
OptiVol technology evolved during this
study. All devices included in this study utilized
the original OptiVol programming algorithms.
The new OptiVol 2.0, included in the Medtronic
Protecta devices, uses modified algorithms to
determine the reference and index values to
improve sensitivity and decrease false positives.22
Adetailed description of these changes is included
in Von Bergen et al.20 How these changes will
affect the utility in pediatrics and CHD is unclear.
Despite the change in technology, this study
does help outline some of the problems with
ITI monitoring in this population. OptiVol 2.0
is currently only available in the Protecta XT
device and may come at higher cost; pediatric
electrophysiologists will need further evidence
to decide if the potential benefit of OptiVol
monitoring is worth the higher cost.
Limitations
This was a retrospective data set. Mild heart
failure exacerbations or medication changes may
have been missed, although the importance of
missing episodes that did not result in hospi-
talization is not convincing. The ITI data were
collected using the OptiVol index report, because
this report is easily interpretable and obtainable by
the physician. It is possible that more significant
findings would have been discovered if raw
impedance measurement data were obtained. The
occurrence of the clinical endpointwas very small.
Conclusions
In this population of pediatric and CHD
patients, ITI analysis was poorly predictive of
clinical heart failure or arrhythmia events, due
to low sensitivity and very low prevalence of
these clinical events in the study population. The
best positive predictive value determined was
4.4% for patients with a systemic right ventricle
(OptiVol Index threshold set at 80 Ohm-days),
though the number of these patients was small.
The current version of OptiVol was not available
at the time of this study, and improvements in
the current algorithms may significantly improve
the functionality in all patients. Ideally, prospec-
tive studies will be needed to determine efficacy
and validity of the system in pediatric and CHD
patients.
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